The relative responsiveness to inhaled leukotriene E4, methacholine and histamine in normal and asthmatic subjects
- PMID: 2852123
The relative responsiveness to inhaled leukotriene E4, methacholine and histamine in normal and asthmatic subjects
Abstract
The relative bronchoconstricting potencies of leukotriene E4 (LTE4) methacholine and histamine have been compared in asthmatic and normal subjects. LTE4 responsiveness in asthmatic subjects, as measured by the dose which produced a 35% fall in specific airways conductance (PD35), ranged from 0.06-24.4 nmol (geom mean 4.1 nmol, n = 20). This was significantly less than the PD35 in normal subjects (range 39.0-370 nmol, geom mean 105 nmol, n= 6; p less than 0.001). There was a correlation between LTE4 and methacholine responsiveness (r = 0.84, p less than 0.001) and between LTE4 and histamine responsiveness (r = 0.79, p less than 0.001). LTE4 was 73 times more potent than methacholine and 112 times more potent than histamine in asthmatic subjects. LTE4 was 20 times more potent than methacholine and 58 times more potent than histamine in normal subjects. LTE4 is a potent bronchoconstrictor agent, and LTE4 responsiveness correlates with both histamine and methacholine responsiveness.
Similar articles
-
Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine.Am Rev Respir Dis. 1990 Nov;142(5):1112-8. doi: 10.1164/ajrccm/142.5.1112. Am Rev Respir Dis. 1990. PMID: 2173457
-
Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways.Am Rev Respir Dis. 1991 Nov;144(5):1053-7. doi: 10.1164/ajrccm/144.5.1053. Am Rev Respir Dis. 1991. PMID: 1659268 Clinical Trial.
-
The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects.J Allergy Clin Immunol. 1988 Oct;82(4):654-60. doi: 10.1016/0091-6749(88)90979-7. J Allergy Clin Immunol. 1988. PMID: 2844876 Clinical Trial.
-
Sulphidopeptide leukotrienes in asthma.Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:415-9. Adv Prostaglandin Thromboxane Leukot Res. 1991. PMID: 1847780 Review.
-
In vivo versus in vitro human airway responsiveness to different pharmacologic stimuli.Am Rev Respir Dis. 1987 Oct;136(4 Pt 2):S58-62. doi: 10.1164/ajrccm/136.4_Pt_2.S58. Am Rev Respir Dis. 1987. PMID: 3310785 Review. No abstract available.
Cited by
-
Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99.Proc Natl Acad Sci U S A. 2016 May 31;113(22):6242-7. doi: 10.1073/pnas.1605957113. Epub 2016 May 16. Proc Natl Acad Sci U S A. 2016. PMID: 27185938 Free PMC article.
-
Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.Thorax. 1995 Sep;50(9):1005-10. doi: 10.1136/thx.50.9.1005. Thorax. 1995. PMID: 8539660 Free PMC article. Review. No abstract available.
-
A proposal to account for the stimulus, the mechanism, and the mediators released in exercise-induced bronchoconstriction.Front Allergy. 2023 Nov 6;4:1004170. doi: 10.3389/falgy.2023.1004170. eCollection 2023. Front Allergy. 2023. PMID: 38026130 Free PMC article. Review.
-
Role of Leukotrienes and Leukotriene Modifiers in Asthma.Pharmaceuticals (Basel). 2010 Jun 2;3(6):1792-1811. doi: 10.3390/ph3061792. Pharmaceuticals (Basel). 2010. PMID: 27713330 Free PMC article. Review.
-
Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.Front Physiol. 2012 Dec 10;3:460. doi: 10.3389/fphys.2012.00460. eCollection 2012. Front Physiol. 2012. PMID: 23233839 Free PMC article.